The Global Viral Vector Purification Market is estimated to reach over USD 18.37 billion by 2030, exhibiting a CAGR of 12.4% during the forecast period.
Over 1,000 cell and gene therapy-related clinical trials are currently underway worldwide. Gene delivery vectors are critical in the development of cell and gene therapies since genetic manipulation is a prerequisite. So far, viral vectors (based on adeno-associated viruses (AAV), adenoviruses, lentiviruses, retroviruses, and other viruses) have been demonstrated to be the most versatile gene delivery tools available, with high transfection efficiencies in both preclinical and clinical settings. Besides that, given the therapeutic efficacy and low side effect profiles of cell and gene therapies, demand for such interventions is expected to rise rapidly, necessitating a proportional increase in demand for appropriate vector systems. Various techniques are currently used to purify viral vectors. Size-based viral purification strategies, such as density-gradient ultracentrifugation, ultrafiltration, precipitation, and size-exclusion chromatography (SEC), have become industry standards over the years.
Following the Covid-19 pandemic, many governments realized the importance of establishing research institutes in the fields of gene therapy and vaccine development. This trend of increasing investment in biotech and pharmaceutical companies is expected to boost the global market for viral vector products. Furthermore, the rising demand for synthetic genes and the untapped market potential are expected to show lucrative growth opportunities for market players in the future.
The global viral vector purification market is segmented on the basis of product type, purification technique type, type of viral vector scope, and scale of operation. By product type, the market is segmented as a kit, prepacked column, resin, cassette, filter plate, capsule, and reagent. The other purification technique type segment includes chromatography, centrifugation, and filtration. The market is segmented by type of viral vector scope into AAV, adenovirus, lentivirus, retrovirus, and others. The other scale of operation segment includes lab-scale, clinical, and commercial.
Based on the type of viral vector scope, the AAV segment is accounted as a significant contributor to the global viral vector purification market.
In 2020, AAV dominated the market with a significant market share. Due to their use in the majority of cell-based gene therapies, the adeno-associated viral vector manufacturing segment is anticipated to grow at the highest CAGR during the forecast period. Some of the significant facts that enable it to occupy a significant share of this vector in the overall market are its ability to integrate with large transgenes and simple production at high levels. Several companies and state organizations have successfully developed an AAV-based vaccine to prevent Covid-19 infection.
The clinical segment witnessed growth at a rapid rate.
In 2020, the clinical segment had the highest market share. The rising engagement of scientific communities in gene and cell therapy research is predicted to raise demand for viral vectors due to the high need for vectors for conducting research.
Furthermore, research organisations, pharmaceutical, and biopharmaceutical enterprises are developing as significant end-users of the market for viral vectors and plasmid DNA synthesis, adding to the launch of advanced medications and the number of gene therapy-based R&D activities. One of these companies, Abeona Therapeutics, is testing AAV9-based gene therapies for CLN1 and CLN3 disorders. As a result, it will fuel market growth.
In the region, the North American viral vector purification market holds a significant revenue share.
North America dominated the global viral vector purification market, accounting for nearly 50% of all revenue in 2020. This region has the highest demand for viral vector CDMO due to the concentration of research and development in the domain of advanced genetic therapies. The United States is the leading country in this region and the world in terms of revenue generation through ADVAC viral vector technology services. In addition, Investments made by federal agencies to expand the region's cell therapy research base are expected to boost the growth of the North American market. Besides, the Asia Pacific region is likely the fastest-growing region due to a growing patient population, increased R&D activities in this field, and other factors. Furthermore, patients from Western countries travel to Asian countries for stem cell therapy because the legal framework in this region is less restrictive.
Furthermore, the region's large population and untapped potential have resulted in a business shift for global firms in this region. Moreover, this region provides reasonably priced manufacturing and operating units for conducting research. These factors are expected to play a significant role in the expansion of the stem cell field in this region, boosting market growth even further.
Some of the major key players in the global viral vector purification market are Agilent Technologies, BIA Separations, Bio-Rad Laboratories, BioVision, Cytiva (formerly GE Lifesciences), Merck, Sartorius, Takara Bio, and Thermo Fisher Scientific.